Fingerprinting the Metabolic and Lipidomic Landscapes of Pancreatic Ductal Adenocarcinoma with MALDI Imaging

PURPOSE: Metabolic reprogramming plays an integral role in progression, immune evasion, and response to treatment in many cancers, including pancreatic ductal adenocarcinoma (PDAC). This study aimed to spatially characterize the metabolic and lipidomic alterations in PDAC and its precursor lesion, intraductal papillary mucinous neoplasm (IPMN), compared to normal/non-neoplastic pancreatic tissue. Experimental details: Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was employed to perform spatial metabolic and lipidomic profiling of human PDAC, IPMN, and normal/non-neoplastic pancreatic tissues. MALDI-MSI provided multiplexed metabolic images of tissue samples at 200 um resolution, allowing spatial characterization of the tumor metabolic landscape. RESULTS: Our data identified metabolic signatures characteristic of PDAC, with several of these altered in IPMN compared to normal/non-neoplastic tissue. The metabolic fingerprint of PDAC was characterized by increased levels of taurine, ascorbic acid, and a variety of lipid species, including most of the phosphatidylcholines and sphingomyelins compared to normal/non-neoplastic pancreas tissue, alongside elevated acetylcarnitine, butyrylcarnitine, and phosphatidylcholine (PC 34:3) relative to IPMN; significant reductions were observed in creatine, malate, lysophosphatidylcholine (LPC 16:0). In contrast, IPMN tissues demonstrated a significant reduction of xanthine, arginine, and tryptophan compared to normal/non-neoplastic pancreas tissue. These metabolic signatures were spatially heterogeneous. CONCLUSION: Our findings provide novel insights into the metabolic and lipidomic underpinnings of PDAC. Metabolic alterations in PDAC were associated with proliferation, immune evasion, and treatment resistance.